BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31921649)

  • 1. The Prognostic Value of Blood-Based Biomarkers in Patients With Testicular Diffuse Large B-Cell Lymphoma.
    Yang J; Guo X; Hao J; Dong Y; Zhang T; Ma X
    Front Oncol; 2019; 9():1392. PubMed ID: 31921649
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic value of absolute lymphocyte/monocyte ratio, red cell distribution width and neutrophil/ lymphocyte ratio in diffuse large B-cell lymphoma patients.
    Hasan KM; Elmeshhedany AY
    Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):61-68. PubMed ID: 34933732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma.
    Feng X; Li L; Wu J; Zhang L; Sun Z; Li X; Wang X; Yu H; Chang Y; Wu X; Zhou Z; Wang G; Li W; Li Z; Zhang X; Zhang M
    Oncologist; 2019 Nov; 24(11):e1123-e1131. PubMed ID: 30952822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS.
    Yang J; Guo X; Wang M; Ma X; Ye X; Lin P
    Sci Rep; 2017 Dec; 7(1):17166. PubMed ID: 29215037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Lymphocyte-Monocyte Ratio and the Platelet-Lymphocyte Ratio at Diagnosis as Independent Prognostic Factors in Primary Gastrointestinal Diffuse Large B Cell Lymphoma.
    Zhao P; Zang L; Zhang X; Chen Y; Yang H; Zhao H; Yu Y; Wang Y; Zhang Y; Wang X
    Indian J Hematol Blood Transfus; 2017 Sep; 33(3):333-341. PubMed ID: 28824234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of inflammation-based indexes in patients with stage III/IV colorectal cancer after adjuvant chemoradiotherapy.
    Yang J; Guo X; Wu T; Niu K; Ma X
    Medicine (Baltimore); 2019 Feb; 98(6):e14420. PubMed ID: 30732196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
    Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
    Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment Inflammatory Indexes as Prognostic Predictors for Survival in Colorectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy.
    Yang J; Xu H; Guo X; Zhang J; Ye X; Yang Y; Ma X
    Sci Rep; 2018 Feb; 8(1):3044. PubMed ID: 29445100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes.
    Wang J; Gao K; Lei W; Dong L; Xuan Q; Feng M; Wang J; Ye X; Jin T; Zhang Z; Zhang Q
    Oncotarget; 2017 Jan; 8(3):5414-5425. PubMed ID: 28036275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic immune inflammation index, ratio of lymphocytes to monocytes, lactate dehydrogenase and prognosis of diffuse large B-cell lymphoma patients.
    Wu XB; Hou SL; Liu H
    World J Clin Cases; 2021 Nov; 9(32):9825-9834. PubMed ID: 34877321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
    Sun F; Zhu J; Lu S; Zhen Z; Wang J; Huang J; Ding Z; Zeng M; Sun X
    BMC Cancer; 2018 Jan; 18(1):5. PubMed ID: 29291712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of Peripheral Blood Lymphocyte/Monocyte ratio (LMR) and Its Ratio to Lactate Dehydrogenase on Prognosis of Patients with Diffuse Large B-Cell Lymphoma].
    Yang D; Su LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1563-1569. PubMed ID: 33067955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment Inflammatory Indexes as Prognostic Predictors of Survival in Patients Suffering From Synovial Sarcoma.
    Cheng Y; Mo F; Pu L; Li Q; Ma X
    Front Oncol; 2019; 9():955. PubMed ID: 31608240
    [No Abstract]   [Full Text] [Related]  

  • 16. The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients.
    Li B; Wang S; Li C; Guo M; Xu Y; Sun X; Yu J; Wang L
    J Cancer; 2019; 10(21):5082-5089. PubMed ID: 31602260
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic Significance of Systemic Immune-Inflammation Index in Patients With Diffuse Large B-Cell Lymphoma.
    Wang Z; Zhang J; Luo S; Zhao X
    Front Oncol; 2021; 11():655259. PubMed ID: 34123808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Peripheral Inflammatory Markers in Preoperative Mucosal Melanoma: A Multicenter Retrospective Study.
    Wang Y; Zhang H; Yang Y; Zhang T; Ma X
    Front Oncol; 2019; 9():995. PubMed ID: 31649874
    [No Abstract]   [Full Text] [Related]  

  • 19. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic values of inflammatory indexes in bevacizumab-treated patients with advanced non-small-cell lung cancer.
    Yang J; Deng M; Bi M; Wang Y; Qiao X; Zhang S
    Future Sci OA; 2022 Mar; 8(5):FSO798. PubMed ID: 35662746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.